US2021115147A1PendingUtilityA1

Fc VARIANTS WITH ALTERED BINDING TO FcRn

Assignee: XENCOR INCPriority: Jul 24, 2007Filed: Aug 4, 2020Published: Apr 22, 2021
Est. expiryJul 24, 2027(~1 yrs left)· nominal 20-yr term from priority
C07K 16/082C07K 2317/52C07K 16/32C07K 16/2863C07K 16/2893C07K 16/22C07K 2317/90C07K 2317/526C07K 16/2878C07K 16/2803A61K 2039/505C07K 2317/524C07K 2317/24
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.

Claims

exact text as granted — not AI-modified
1 .- 24 . (canceled) 
     
     
         25 . A protein comprising an Fc variant as compared to a parent IgG Fc region, said variant Fc region comprising an amino acid substitution selected from the group consisting of Q311V, H285D and N286D, wherein numbering is according to the EU index in Kabat et al. 
     
     
         26 . An antibody comprising an Fc variant as compared to a parent IgG Fc region, said variant Fc region comprising an amino acid substitution selected from the group consisting of Q311V, H285D and N286D, wherein numbering is according to the EU index in Kabat et al. 
     
     
         27 . A nucleic acid encoding the protein of  claim 25 . 
     
     
         28 . A nucleic acid encoding the heavy chain of said antibody of  claim 26 . 
     
     
         29 . An expression vector comprising the nucleic acid of  claim 27 . 
     
     
         30 . A host cell comprising the expression vector of  claim 29 . 
     
     
         31 . A method of making a protein comprising an Fc variant as compared to a parent IgG Fc region, said variant Fc region comprising an amino acid substitution selected from the group consisting of Q311V, H285D and N286D, wherein numbering is according to the EU index in Kabat et al., said method comprising culturing the host cell of  claim 30  under conditions wherein said antibody is expressed and recovering said antibody.

Join the waitlist — get patent alerts

Track US2021115147A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.